Management

Dr. Tony Buss (President & CEO)

Dr. Tony Buss is the President and CEO of MerLion Pharmaceuticals. He has held senior research and management positions with major pharmaceutical and agrochemical companies, including 7 years with Pfizer, 6 years with Schering AG (both in the UK and Germany) and 13 years with GlaxoSmithKline. He joined the Centre for Natural Product Research, Singapore, in 2000 as Head of the Centre, before its incorporation as MerLion Pharmaceuticals Pte Ltd in 2002. Dr. Buss is a graduate of the Royal Institute of Chemistry, London. He was awarded a MSc from the University of East Anglia in 1978 and received his PhD in 1981 from the University of Cambridge, England.

Mr. David Dally qualified as a chartered accountant with Ernst and Young in London, UK. He joined Amersham plc in 1991 and held a number finance roles including Manager of Strategic Planning, which included undertaking M&A activity in Japan for Amersham's diagnostic business. This was followed by the role of VP Finance North America for Amersham Bioscience, managing the merger of Amersham Life Science with Pharmacia Biotech. Since 2002 David has held CFO positions at Kudos Pharmaceuticals Ltd, an early-stage drug discovery and development in Cambridge, UK, which was sold to Astra Zeneca for $210m, and Rhytec Ltd, a medical devices company.
 

Dr. Martin Everett joined MerLion in 2005, initially as Head of Biological Sciences, becoming Head of Research in 2008. Before joining MerLion he worked at Glaxo SmithKline in the UK on anti-tubercular drug discovery and led a team performing automated high throughput screening of enzyme targets within the Molecular Screening department. Between 1993-96 he was a postdoctoral fellow in the Antibiotic Research Group at the University of Birmingham, investigating the molecular causes of antibiotic resistance in clinical and veterinary pathogens. He obtained a Bsc in Microbiology from University of Wales, College of Swansea, in 1987 and a PhD from University of Bristol in 1992.
 

Dr. Andreas Vente (Managing Director MerLion Pharmaceuticals GmbH)

Dr. Andreas Vente joined MerLion in 2006 in conjunction with the acquisition of Combinature Biopharm AG. Before becoming Managing Director of MerLion’s drug development subsidiary in Berlin in 2009, he was head of project management and non-clinical development. For Combinature Biopharm AG he worked as COO and in various management positions. Between 1998 and 2000 he was the Head of the Laboratories of the RZPD German Resource Center for Genome Research GmbH. Earlier, he worked as a postdoctoral fellow at the ETH, Zürich and the German Cancer Research Center, Heidelberg. Dr. Vente obtained an MSc in Biology from the University of Cologne, Germany, in 1992 and a PhD at the Max Planck Institute for Plant Breeding Research, Cologne, in 1996.